If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Covaxin was earlier approved for children 12-18 years of age
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Subscribe To Our Newsletter & Stay Updated
